Skip Navigation Links

Bookmark and Share
GMAX Biopharm gives first does of anti-body drug treating PAH in phase 1B trial
HANGZHOU, China, Oct. 26, 2020 /PRNewswire/ -- Gmax Biopharm today announces that the first dose of GMA301 was given to the patient in its phase 1B trial to investigate the drug efficacy to treat pulmonary arterial hyp...

Full "IntellAsia: Resources" article

Disclaimer | Terms Of Use And Privacy Statement

© Metals News. All rights reserved.